Christy Jones Sells 1,406 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 1,406 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $15.00, for a total transaction of $21,090.00. Following the transaction, the director owned 25,994 shares in the company, valued at approximately $389,910. This trade represents a 5.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christy Jones also recently made the following trade(s):

• On Thursday, June 4th, Christy Jones sold 2,811 shares of Beta Bionics stock. The stock was sold at an average price of $14.00, for a total transaction of $39,354.00.
• On Thursday, May 21st, Christy Jones sold 1,998 shares of Beta Bionics stock. The stock was sold at an average price of $9.95, for a total transaction of $19,880.10.

Beta Bionics Price Performance

Beta Bionics stock traded up $1.18 during mid-day trading on Thursday, reaching $15.91. 1,092,973 shares of the company traded hands, compared to its average volume of 1,140,386. The firm’s fifty day moving average is $11.97 and its two-hundred day moving average is $15.67. The company has a market capitalization of $708.95 million, a price-to-earnings ratio of -10.54 and a beta of 3.40. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. The business had revenue of $27.63 million during the quarter. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. As a group, equities research analysts predict that Beta Bionics, Inc. will post -2.22 earnings per share for the current year.

Institutional Trading of Beta Bionics

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Beta Bionics by 213.5% during the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after acquiring an additional 1,509,217 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Beta Bionics in the 4th quarter worth approximately $40,437,000. Eversept Partners LP grew its stake in shares of Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares during the period. 12 West Capital Management LP acquired a new stake in shares of Beta Bionics during the 4th quarter worth approximately $17,520,000. Finally, Bruce & Co. Inc. purchased a new position in shares of Beta Bionics during the 1st quarter valued at approximately $5,518,000.

Wall Street Analysts Forecast Growth

BBNX has been the topic of a number of research reports. Stifel Nicolaus cut their price objective on Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Bank of America dropped their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, May 18th. Truist Financial cut their price target on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, April 15th. Wall Street Zen lowered shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Finally, Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $19.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.